Validation of a miRNA biomarker signature for early detection of lung cancer.

• Conditions: C34.1; Upper lobe, bronchus or lung

• Registration Number: DRKS00031791
• Lead Sponsor: Hummingbird Diagnostics

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-03-15
• Study Start: 2023-05-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 359

Inclusion Criteria

Presence of appropriate sample materials (here PAXgene tubes) in Biobank for miRNA analysis.

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of this study is to evaluate a novel miRNA-based method for early detection of lung cancer (NSCLC) in a cohort of patients with suspicious X-ray/CT findings. In this study, 360 preserved patient samples will be selected from a biobank.

Secondary Outcome Measures

Name	Time	Method
The existing miRNA signature will applied to these samples and the sensitivity as well as specificity will be determined.